66411-22-1 Usage
General Description
8-Amino-2,3-dihydrobenzo[1,4]dioxine-5-carboxylic acid is a chemical compound with a molecular formula C10H9NO4. It is a derivative of benzo[1,4]dioxine and contains an amino group and a carboxylic acid functional group. 8-Amino-2,3-dihydrobenzo[1,4]dioxine-5-carboxylic acid has potential applications in pharmaceutical and organic synthesis due to its unique structure and reactivity. It can be used as a building block in the synthesis of various pharmaceutical compounds and other biologically active molecules. Its chemical properties make it a valuable intermediate in the production of drugs and other compounds with medicinal properties. Additionally, it may have potential applications in research and development of new chemical compounds with therapeutic uses.
Check Digit Verification of cas no
The CAS Registry Mumber 66411-22-1 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 6,6,4,1 and 1 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 66411-22:
(7*6)+(6*6)+(5*4)+(4*1)+(3*1)+(2*2)+(1*2)=111
111 % 10 = 1
So 66411-22-1 is a valid CAS Registry Number.
InChI:InChI=1/C9H9NO4/c10-6-2-1-5(9(11)12)7-8(6)14-4-3-13-7/h1-2H,3-4,10H2,(H,11,12)
66411-22-1Relevant articles and documents
MDM2 DEGRADERS AND USES THEREOF
-
Paragraph 001773; 001778-001779; 001916; 001921-001922, (2021/09/26)
The present invention relates to compounds and methods useful for the modulation of mouse double minute 2 homolog ("MDM2") protein via ubiquitination and/or degradation by compounds according to the present invention.
2-PHENYLAMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE
-
Page/Page column 115; 116, (2013/06/27)
Specific Compounds of formula (I): or pharmaceutically acceptable salts thereof, wherein m, X, R, R2, R3, R, R6 and R7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.
